• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [24038 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pasireotide (new therapeutic indication) - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2015     National Institute for Health and Care Excellence (NICE) Rifaximin for preventing episodes of overt hepatic encephalopathy. NICE technology appraisal guidance 337
2015     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry. Part III: carnitine uptake deficiency (CUD); short-chain acyl-CoA dehydrogenase deficiency (SCADD); very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)]
2015     NIHR Health Services and Delivery Research programme The dynamics of quality: a national panel study of evidence-based standards
2015     Health Quality Ontario (HQO) Mitral valve clip for treatment of mitral regurgitation: an evidence-based analysis
2015     Adelaide Health Technology Assessment (AHTA) Endovascular clot retrieval with thrombolysis for ischaemic stroke
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Objectively derived approach for the development of search strategies in bibliographic databases]
2015     National Institute for Health and Care Excellence (NICE) Omalizumab for previously treated chronic spontaneous urticaria. NICE technology appraisal guidance 339
2015     National Institute for Health and Care Excellence (NICE) VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions. NICE diagnostics guidance 19
2015     NIHR Health Services and Delivery Research programme A national study of practice patterns in UK renal units in the use of dialysis and conservative kidney management to treat people aged 75 years and over with chronic kidney failure
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Reablement for seniors experience a loss of autonomy]
2015     Adelaide Health Technology Assessment (AHTA) Ultra-filtration for patients with decompensated heart failure
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Invitation and fact sheet for breast cancer Screening - Rapid report]
2015     National Institute for Health and Care Excellence (NICE) Ustekinumab for treating active psoriatic arthritis. NICE technology appraisal guidance 340
2015     National Institute for Health and Care Excellence (NICE) Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay). NICE diagnostics guidance 18
2015     NIHR Health Services and Delivery Research programme Using clinical practice variations as a method for commissioners and clinicians to identify and prioritise opportunities for disinvestment in health care: a cross-sectional study, systematic reviews and qualitative study
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Information brief concerning palliative care day centres]
2015     Adelaide Health Technology Assessment (AHTA) Blood and stool biomarker testing for colorectal cancer screening
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Continuous interstitial glucose monitoring (CGM) with real-time measurement devices in insulin-dependent diabetes mellitus]
2015     National Institute for Health and Care Excellence (NICE) Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. NICE technology appraisal guidance 341
2015     NIHR Health Services and Delivery Research programme The delivery of chemotherapy at home: an evidence synthesis
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Insulin pumps in the treatment of type 1 diabetes]
2015     NIHR Public Health Research (PHR) programme The impact on health inequalities of approaches to community engagement in the New Deal for Communities regeneration initiative: a mixed-methods evaluation
2015     Adelaide Health Technology Assessment (AHTA) Pressurised intraperitoneal aerosol chemotherapy
2015     Gesundheit Osterreich GmbH (GOeG) [Non-drug prevention and treatment of Alzheimer's dementia and mixed dementia]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nintedanib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     National Institute for Health and Care Excellence (NICE) Vedolizumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 342
2015     NIHR Health Services and Delivery Research programme The management of individuals with enduring moderate to severe mental health needs: a participatory evaluation of client journeys and the interface of mental health services with the criminal justice system in Cornwall
2015     Health Council of the Netherlands Gezondheidsraad (GR) [Population Screening Act: prevalence of gastrointestinal tract disorders studied with a video capsule]
2015     Adelaide Health Technology Assessment (AHTA) High-frequency spinal cord stimulation and dorsal root ganglion stimulation for chronic pain
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     National Institute for Health and Care Excellence (NICE) Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 343
2015     NIHR Health Services and Delivery Research programme Do higher primary care practice performance scores predict lower rates of emergency admissions for persons with serious mental illness? An analysis of secondary panel data
2015     Adelaide Health Technology Assessment (AHTA) Leadless Pacemaker
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tafluprost/timolol - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     National Institute for Health and Care Excellence (NICE) Naloxegol for treating opioid-induced constipation. NICE technology appraisal guidance 345
2015     NIHR Health Services and Delivery Research programme Service user engagement and health service reconfiguration: a rapid evidence synthesis
2015     NIHR Health Technology Assessment programme Double-blind randomised controlled trial of percutaneous tibial nerve stimulation versus sham electrical stimulation in the treatment of faecal incontinence: CONtrol of Faecal Incontinence using Distal NeuromodulaTion (the CONFIDeNT trial)
2015     Adelaide Health Technology Assessment (AHTA) Circulating tumour DNA assays
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Stem cell transplantation for multiple myeloma (follow-up commission to Commission N05-03C)]
2015     National Institute for Health and Care Excellence (NICE) Aflibercept for treating diabetic macular oedema. NICE technology appraisal guidance 346
2015     NIHR Health Services and Delivery Research programme Towards a framework for enhancing procurement and supply chain management practice in the NHS: lessons for managers and clinicians from a synthesis of the theoretical and empirical literature
2015     NIHR Health Services and Delivery Research programme Ensuring comparisons of health-care providers are fair: development and validation of risk prediction models for critically ill patients
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound screening for abdominal aortic aneurysms]
2015     National Institute for Health and Care Excellence (NICE) Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer. NICE technology appraisal guidance 347
2015     NIHR Health Services and Delivery Research programme Knowledge exchange in health-care commissioning: case studies of the use of commercial, not-for-profit and public sector agencies, 2011-14
2015     New Zealand National Health Committee (NHC) Epidermal growth factor receptor gene mutation analysis testing assessment
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2015     National Institute for Health and Care Excellence (NICE) Everolimus for preventing organ rejection in liver transplantation. NICE technology appraisal guidance 348
2015     Adelaide Health Technology Assessment (AHTA) An assessment of nucleic acid amplification testing for active mycobacterial infection
2015     New Zealand National Health Committee (NHC) Percutaneous Left Atrial Appendage Occlusion (LAAO) for the prevention of stroke in non-valvular atrial fibrillation (AF) in the New Zealand health system
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dasabuvir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcorneal electrical stimulation for retinitis pigmentosa (Addendum to commission E14-07)]
2015     National Institute for Health and Care Excellence (NICE) Secukinumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 350
2015     Penn Medicine Center for Evidence-based Practice (CEP) Algorithms for the management of massive hemoptysis in the acute care setting
2015     New Zealand National Health Committee (NHC) Age-related macular degeneration
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ombitasvir/paritaprevir/ritonavir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     National Institute for Health and Care Excellence (NICE) Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of antiplatelet therapy (terminated appraisal). NICE technology appraisal guidance 351
2015     Penn Medicine Center for Evidence-based Practice (CEP) Nurse practitioner models of preceptorship
2015     New Zealand National Health Committee (NHC) Haematuria: presentation, diagnostic pathway and alternative diagnostic options
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aclidinium/formoterol - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     National Institute for Health and Care Excellence (NICE) Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy. NICE technology appraisal guidance 352
2015     Penn Medicine Center for Evidence-based Practice (CEP) Oral rehydration therapy for adults with acute infectious gastrointestinal disease
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dulaglutide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     National Institute for Health and Care Excellence (NICE) Bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal). NICE technology appraisal guidance 353
2015     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of foam sclerotherapy, endovenous laser ablation and surgery for varicose veins: results from the CLASS trial
2015     Agency for Healthcare Research and Quality (AHRQ) Systematic review for effectiveness of hyaluronic acid in the treatment of severe degenerative joint disease (DJD) of the knee
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ledipasvir/sofosbuvir (Addendum to Commission A14-44)]
2015     National Institute for Health and Care Excellence (NICE) Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism. NICE technology appraisal guidance 354
2015     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination against pertussis: aims and strategy
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Screening for visual impairment in children younger than 6 years - rapid report]
2015     National Institute for Health and Care Excellence (NICE) Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation. NICE technology appraisal guidance 355
2015     Penn Medicine Center for Evidence-based Practice (CEP) Hospitalist clinics for post-discharge care
2015     Health Council of the Netherlands Gezondheidsraad (GR) 4,4'-Methylenedianiline - Health-based calculated occupational cancer risk values
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apremilast - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab. NICE technology appraisal guidance 357
2015     NIHR Health Technology Assessment programme Smoking Cessation Intervention for severe Mental Ill Health Trial (SCIMITAR): a pilot randomised control trial of the clinical effectiveness and cost-effectiveness of a bespoke smoking cessation service
2015     Penn Medicine Center for Evidence-based Practice (CEP) Pre-operative cardiovascular surgery patient education
2015     NIHR Health Technology Assessment programme The clinical effectiveness and cost-effectiveness of open mesh repairs in adults presenting with a clinically diagnosed primary unilateral inguinal hernia who are operated in an elective setting: systematic review and economic evaluation
2015     Health Council of the Netherlands Gezondheidsraad (GR) 1,4-Dioxane - re-evaluation of the carcinogenicity and genotoxicity
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Stents for the treatment of intracranial artery stenosis: VISSIT study and acute treatment in Germany (working paper on commission N14-01)]
2015     National Institute for Health and Care Excellence (NICE) Tolvaptan for treating autosomal dominant polycystic kidney disease. NICE technology appraisal guidance 358
2015     Health Council of the Netherlands Gezondheidsraad (GR) 2,6-Xylidine - re-evaluation of the carcinogenicity and genotoxicity
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nintedanib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2015     National Institute for Health and Care Excellence (NICE) Idelalisib for treating chronic lymphocytic leukaemia. NICE technology appraisal guidance 359
2015     Health Council of the Netherlands Gezondheidsraad (GR) Methodology for the evaluation of the evidence for the Dutch dietary guidelines 2015 - background document
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Treatment of haemophilia patients - Rapid report]
2015     National Institute for Health and Care Excellence (NICE) Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 362
2015     Penn Medicine Center for Evidence-based Practice (CEP) Inpatient mental health unit décor
2015     Health Council of the Netherlands Gezondheidsraad (GR) Shiftwork and health risks: possibilities for prevention
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin degludec (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     National Institute for Health and Care Excellence (NICE) Ledipasvir-sofosbuvir for treating chronic hepatitis C. NICE technology appraisal guidance 363
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tafluprost/timolol (Addendum to Commission A14-49)]
2015     National Institute for Health and Care Excellence (NICE) Ombitasvir-paritaprevir-ritonavir with or without dasabuvir for treating chronic hepatitis C. NICE technology appraisal guidance 365
2015     Health Information and Quality Authority (HIQA) Guidance on budget impact analysis of health technologies in Ireland
2015     NIHR Health Technology Assessment programme Psychological and psychosocial interventions for cannabis cessation in adults: a systematic review short report
2015     Penn Medicine Center for Evidence-based Practice (CEP) Locking solutions for central venous catheters
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     National Institute for Health and Care Excellence (NICE) Pembrolizumab for advanced melanoma not previously treated with ipilimumab. NICE technology appraisal guidance 366
2015     NIHR Health Services and Delivery Research programme Tele-First: telephone triage as an alternative to face to face contact in general practice